Inventor · disambiguated record
John S. Lollar
Also filed as: LOLLAR JOHN S
24 granted patents·11 pending applications·1,041 citations·filing 1992–2025
97Inventor score
Files withUNIV EMORY22LOLLAR JOHN S6EXPRESSION THERAPEUTICS INC1EXPRESSION THERAPEUTICS LLC1IPSEN BIOPHARM LTD1
Top patents by PatentIndex Score
35 records- 0198US6458563B1Modified factor VIIIUNIV EMORY·Filed 2000·Granted Oct 1, 2002·175 cites·10 claims
- 0296US7560107B2Modified factor VIIIUNIV EMORY·Filed 2006·Granted Jul 14, 2009·23 cites·8 claims
- 0394US6376463B1Modified factor VIIIUNIV EMORY·Filed 1999·Granted Apr 23, 2002·108 cites·6 claims
- 0494US5859204AModified factor VIIIUNIV EMORY·Filed 1996·Granted Jan 12, 1999·122 cites·22 claims
- 0593US5364771AHybrid human/porcine factor VIIIUNIV EMORY·Filed 1992·Granted Nov 15, 1994·129 cites·19 claims
- 0691US6759216B1Glycosylated, low antigenicity low immunogenicity factor VIIIUNIV EMORY·Filed 1999·Granted Jul 6, 2004·47 cites·1 claims
- 0789US7635763B2Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of useEXPRESSION THERAPEUTICS LLC·Filed 2004·Granted Dec 22, 2009·16 cites·14 claims
- 0889US6517830B1Compositions and methods for the expression of factor VIII polypeptides and uses thereforUNIV EMORY·Filed 2000·Granted Feb 11, 2003·21 cites·12 claims
- 0988US7122634B2Modified factor VIIIUNIV EMORY·Filed 2004·Granted Oct 17, 2006·22 cites·6 claims
- 1087US8188246B2Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of useLOLLAR JOHN S·Filed 2009·Granted May 29, 2012·7 cites·11 claims
- 1187US5744446AHybrid human/animal factor VIIIUNIV EMORY·Filed 1995·Granted Apr 28, 1998·84 cites·20 claims
- 1286US8519111B2Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of useLOLLAR JOHN S·Filed 2012·Granted Aug 27, 2013·7 cites·2 claims
- 1386US7033791B2Nucleic acid molecules encoding modified factor VIII proteins, expression products, and methods of making the sameUNIV EMORY·Filed 2002·Granted Apr 25, 2006·15 cites·19 claims
- 1486US7012132B2Modified factor VIIIUNIV EMORY·Filed 2002·Granted Mar 14, 2006·16 cites·2 claims
- 1584US7576181B2Method of administering porcine B-domainless fVIIIIPSEN BIOPHARM LTD·Filed 2006·Granted Aug 18, 2009·7 cites·24 claims
- 1684US6852537B2Transgenic circulating endothelial cellsUNIV MINNESOTA EMORY UNIVERSIT·Filed 2001·Granted Feb 8, 2005·27 cites·17 claims
- 1784US6770744B2Modified factor VIIIUNIV EMORY·Filed 2001·Granted Aug 3, 2004·51 cites·43 claims
- 1881US6180371B1Modified factor VIIIUNIV EMORY·Filed 1998·Granted Jan 30, 2001·45 cites·25 claims
- 1981US5663060AHybrid human/animal factor VIIIUNIV EMORY·Filed 1994·Granted Sep 2, 1997·52 cites·23 claims
- 2080US8101718B2Methods of administering porcine B-domainless fVIIILOLLAR JOHN S·Filed 2009·Granted Jan 24, 2012·4 cites·8 claims
- 2177US8501694B2Method of administering porcine B-domainless fVIIILOLLAR JOHN S·Filed 2012·Granted Aug 6, 2013·3 cites·4 claims
- 2275US5583209AHybrid human/porcine factor VIIIUNIV EMORY·Filed 1994·Granted Dec 10, 1996·31 cites·10 claims
- 2369US2009325881A1Modified factor viiiUNIV EMORY·Filed 2009·Application pending·0 cites
- 2466US8951515B2Modified factor VIIILOLLAR JOHN S·Filed 2012·Granted Feb 10, 2015·0 cites·5 claims
- 2565US5888974AHybrid human/animal factor VIIIUNIV EMORY·Filed 1995·Granted Mar 30, 1999·29 cites·2 claims
- 2658US2014193441A1Method of Administering Porcine B-domainless fVIIILOLLAR JOHN S·Filed 2013·Application pending·0 cites
- 2758US2015352190A1Modified Factor VIIIUNIV EMORY·Filed 2015·Application pending·0 cites
- 2856US2006013805A1Transgenic circulating endothelial cellsUNIV EMORY·Filed 2004·Application pending·0 cites
- 2956US2005009148A1Glycosylated, low antigenicity, low immunogenicity factor VIIIFiled 2004·Application pending·0 cites
- 3055US2003129174A1Compositions and methods for the expression of factor VIII polypeptides and uses thereforUNIV EMORY·Filed 2002·Application pending·0 cites
- 3155US2005123997A1Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopesFiled 2004·Application pending·0 cites
- 3254US2017119857A1Method of Administering Porcine B-Domainless fVIIIUNIV EMORY·Filed 2016·Application pending·0 cites
- 3351US2004249134A1Factor viii c2 domain variantsFiled 2002·Application pending·0 cites
- 3448US2025281544A1Gene therapy for bleeding disordersEXPRESSION THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3543US2016030529A1Targeted elimination of factor viii immune cellsUNIV EMORY·Filed 2014·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →